Integrated Clinical Systems, Inc. announced the opening of a European branch office in Switzerland
Integrated Clinical Systems, Inc. (ICS) www.i-review.com, developers of Integrated Review™ & JReview®, the world’s most comprehensive clinical review and analysis software tool, today announced the opening of a European branch office in Switzerland. The office will be the company’s first location in Europe, dedicated to client management and business development in Europe, Middle East & Africa (EMEA).
ICS’s EMEA branch office is located in Lausanne, Switzerland. It will be led by Dr. Mark Demesmaeker, Director of EMEA & Asia Operations, who joined the company in January from TIBCO Spotfire where he headed the clinical analytics practice.
Eric S. Herbel, President of ICS said, “Our European customers have been frequently asking for an ICS regional presence and support. As a consequence, we have decided to set up a European branch office in order to better serve our European customers and also expand our footprint in the EMEA region.”
“About 40% of our customer base is located in Europe and the business is constantly growing” says Dr. Demesmaeker. “Many of our clients are global corporations with regional headquarters. Expanding and scaling a high-quality customer service and business development team is a key driver to our continued success in the market.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.